IMD - Innovative Medical Devices is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Precinct One has 1.1 million residents. County Commissioners operate parks, build road/bridge projects and offer senior and youth programs.
For 30 years, Accra has improved the lives of Minnesotans by providing individualized homecare services to people with disabilities and older adults, most of whom are Medicaid enrollees. Accra is a nonprofit organization that operates in all counties throughout Minnesota and has offices across the state, providing a familiar presence in local communities. Accra`s self-directed services support the independence of children, adolescents, and adults with disabilities, chronic diseases, behavioral diagnoses, and mental illnesses, who need assistance with personal care in the home and activities of daily living.
Cell Science Systems Limited Corp is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Deerfield Beach, FL. To find more information about Cell Science Systems Limited Corp, please visit www.alcat.com
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.